Esteemed epidemiologist: ‘We must start treating immediately’ with hydroxychloroquine

Contrary to popular politicized opinion, hydroxychloroquine can be highly effective against COVID-19, according to a seasoned epidemiology professor at the Yale School of Public Health.

The only caveats are that the much-debated drug must be administered early in the virus’s attack and, when doable, combined with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.

So maintains Harvey A. Risch, MD, PhD, whose credentials include authoring more than 300 peer-reviewed studies and holding senior positions on editorial boards at several leading scientific journals.

Risch’s opinion piece is running in Newsweek.

After summarizing evidence of hydroxychloroquine’s efficacy against COVID and contextualizing widely disseminated warnings about its potential for causing cardiac arrhythmia, Risch pleads with the public to place hard science over hot passion.

“In the future, I believe this misbegotten episode regarding hydroxychloroquine will be studied by sociologists of medicine as a classic example of how extra-scientific factors overrode clear-cut medical evidence. But for now, reality demands a clear, scientific eye on the evidence and where it points,” he writes.

“For the sake of high-risk patients, for the sake of our parents and grandparents, for the sake of the unemployed, for our economy and for our polity, especially those disproportionally affected, we must start treating immediately.”

Click here to read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?